Ligand Pharmaceuticals
LGND
LGND
362 hedge funds and large institutions have $3.61B invested in Ligand Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 156 increasing their positions, 92 reducing their positions, and 84 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
362
Holders Change
-23
Holders Change %
-5.97%
% of All Funds
8.08%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.13%
New
63
Increased
156
Reduced
92
Closed
84
Calls
$106M
Puts
$147M
Net Calls
-$40.6M
Net Calls Change
-$71.7M
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$98.6M |
| 2 |
Millennium Management
New York
|
+$61.2M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$35.9M |
| 4 |
Jennison Associates
New York
|
+$26.1M |
| 5 |
Two Sigma Investments
New York
|
+$25.8M |
Top Sellers
| 1 |
BlackRock
New York
|
-$79.3M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$71.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$42.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$21.8M |
